Literature DB >> 28945149

Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis.

N Abdel-Wahab1,2, S Talathi3, M A Lopez-Olivo1, M E Suarez-Almazor1.   

Abstract

Objective The objective of this paper is to conduct a systematic review and meta-analysis on the risk of developing elevated antiphospholipid (aPL) antibodies and related thromboembolic and/or pregnancy events following a viral infection. Method We searched Medline, EMBASE, Web of Science, PubMed ePubs, and Cochrane Central Register of Controlled Trials through June 2016. Independent observational studies of elevated aPL antibodies in patients with a viral infection compared with controls or patients with lupus were included. Results We analyzed 73 publications for 60 studies. Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) were most commonly reported. Compared with healthy controls, patients with HIV were more likely to develop elevated anticardiolipin (aCL) antibodies (risk ratio (RR) 10.5, 95% confidence interval (CI) 5.6-19.4), as were those with HCV (RR 6.3, 95% CI 3.9-10.1), hepatitis B virus (HBV) (RR 4.2, 95% CI 1.8-9.5), and Epstein-Barr virus (EBV) (RR 10.9 95% CI 5.4-22.2). The only statistically significant increased risk for anti-β2-glycoprotein I (anti-β2-GPI) antibodies was observed in patients with HCV (RR 4.8 95% CI 1.0-22.3). Compared with patients with lupus, patients with HIV were more likely to develop elevated aCL antibodies (RR 1.8, 95% CI 1.3-2.6), and those with EBV, elevated anti-β2-GPI antibodies (RR 2.2, 95% CI 1.3-3.9). Thromboembolic events were most prevalent in patients with elevated aPL antibodies who had HCV (9.1%, 95% CI 3.0-18.1), and HBV (5.9%, 95% CI 2.0-11.9) infections, and pregnancy events were most prevalent in those with parvovirus B19 (16.3%, 95% CI 0.78-45.7). However, compared to virus-infected patients with negative aPL antibodies, the only statistically significant increased risk was observed in those with HCV and positive aPL. Conclusions Viral infection can increase the risk of developing elevated aPL antibodies and associated thromboembolic events. Results are contingent on the reported information.

Entities:  

Keywords:  Antiphospholipid syndrome; anticardiolipin antibodies; infection; meta-analysis; observational studies; systematic review; thromboembolic events

Mesh:

Substances:

Year:  2017        PMID: 28945149     DOI: 10.1177/0961203317731532

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  38 in total

Review 1.  Role of Infectious Diseases in the Antiphospholipid Syndrome (Including Its Catastrophic Variant).

Authors:  Claudia Mendoza-Pinto; Mario García-Carrasco; Ricard Cervera
Journal:  Curr Rheumatol Rep       Date:  2018-08-20       Impact factor: 4.592

Review 2.  How to recognize and manage COVID-19-associated coagulopathy.

Authors:  Gloria F Gerber; Shruti Chaturvedi
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 3.  Pathogenesis and treatment of autoimmune rheumatic diseases.

Authors:  Eric Liu; Andras Perl
Journal:  Curr Opin Rheumatol       Date:  2019-05       Impact factor: 5.006

4.  Perioperative Thromboelastometry for Adult Living Donor Liver Transplant Recipients with a Tendency to Hypercoagulability: A Prospective Observational Cohort Study.

Authors:  Yasmin Kamel; Ashraf Hassanin; Abdel Rahman Ahmed; Emad Gad; Mohamed Afifi; Magdy Khalil; Klaus Görlinger; Khaled Yassen
Journal:  Transfus Med Hemother       Date:  2018-08-24       Impact factor: 3.747

5.  Clinicopathologic findings of chronic active Epstein-Barr virus infection in adults: A single-center retrospective study in China.

Authors:  Jing Lin; Haicong Wu; Lei Gu; Xia Wu; Miaofang Su; Haiyan Lin; Bang Liu; Jiaolong Zheng; Xuan Mei; Dongliang Li
Journal:  Clin Exp Med       Date:  2021-02-26       Impact factor: 3.984

6.  Antiphospholipid antibodies in COVID-19: a meta-analysis and systematic review.

Authors:  Muhanad Taha; Lobelia Samavati
Journal:  RMD Open       Date:  2021-05

Review 7.  Antiphospholipid antibodies in critically ill COVID-19 patients with thromboembolism: cause of disease or epiphenomenon?

Authors:  Vittorio Pavoni; Lara Gianesello; Andrew Horton
Journal:  J Thromb Thrombolysis       Date:  2021-05-10       Impact factor: 2.300

8.  Lupus Anticoagulant Single Positivity During the Acute Phase of COVID-19 Is Not Associated With Venous Thromboembolism or In-Hospital Mortality.

Authors:  Nicolas Gendron; Marie-Agnès Dragon-Durey; Richard Chocron; Luc Darnige; Georges Jourdi; Aurélien Philippe; Camille Chenevier-Gobeaux; Jérôme Hadjadj; Jérôme Duchemin; Lina Khider; Nader Yatim; Guillaume Goudot; Daphné Krzisch; Benjamin Debuc; Laetitia Mauge; Françoise Levavasseur; Frédéric Pene; Jeremy Boussier; Elise Sourdeau; Julie Brichet; Nadège Ochat; Claire Goulvestre; Christophe Peronino; Tali-Anne Szwebel; Franck Pages; Pascale Gaussem; Charles-Marc Samama; Cherifa Cheurfa; Benjamin Planquette; Olivier Sanchez; Jean-Luc Diehl; Tristan Mirault; Michaela Fontenay; Benjamin Terrier; David M Smadja
Journal:  Arthritis Rheumatol       Date:  2021-09-22       Impact factor: 15.483

Review 9.  Is the Endothelium the Missing Link in the Pathophysiology and Treatment of COVID-19 Complications?

Authors:  Pedro Castro; Marta Palomo; Ana Belen Moreno-Castaño; Sara Fernández; Sergi Torramadé-Moix; Georgina Pascual; Julia Martinez-Sanchez; Edward Richardson; Adrián Téllez; Josep M Nicolas; Enric Carreras; Paul G Richardson; Juan José Badimon; Gines Escolar; Maribel Diaz-Ricart
Journal:  Cardiovasc Drugs Ther       Date:  2021-06-07       Impact factor: 3.947

10.  Systematic Review of Antiphospholipid Antibodies in COVID-19 Patients: Culprits or Bystanders?

Authors:  Thomas Foret; Virginie Dufrost; Lucie Salomon Du Mont; Patricia Costa; Benjamin Lefevre; Patrick Lacolley; Veronique Regnault; Stephane Zuily; Denis Wahl
Journal:  Curr Rheumatol Rep       Date:  2021-07-03       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.